Skip to main content
ABT
NYSE Life Sciences

Abbott Laboratories Completes $20 Billion Senior Notes Offering for Exact Sciences Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$112.65
Mkt Cap
$195.75B
52W Low
$105.27
52W High
$139.15
52W Position info
7.0% above low
Off High info
19% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ABT is trading near its 52-week low of $105.27 (7.0% above the low).

Summary

Abbott Laboratories has completed its $20 billion senior notes offering, securing substantial capital to fund the acquisition of Exact Sciences Corporation.


Key Events · Financing and Capital Events · ABT

  • Debt Issuance Completed

    Abbott Laboratories successfully issued $20 billion in senior notes across multiple tranches on March 9, 2026.

  • Acquisition Funding

    The proceeds from the notes offering are primarily intended to finance the previously announced $21 billion acquisition of Exact Sciences Corporation.

  • Special Redemption Clause

    The notes include a provision for mandatory redemption at 101% of principal if the Exact Sciences acquisition is not completed by February 17, 2027.

  • Follows Prior Disclosures

    This filing confirms the completion of the offering previously detailed in FWP and 424B5 filings on February 23 and February 25, 2026, respectively.


Analysis · ABT · Life Sciences

This 8-K announces the successful completion of Abbott Laboratories' $20 billion senior notes offering, a critical step in financing its previously announced $21 billion acquisition of Exact Sciences Corporation. The multi-tranche debt issuance, with maturities extending to 2066, secures the necessary capital for this significant strategic transaction. The offering includes a special mandatory redemption clause, providing bondholder protection if the acquisition is not consummated. This filing confirms the execution of the financing strategy, removing a key uncertainty related to the acquisition.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABT was trading at $112.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $195.7B. The 52-week trading range was $105.27 to $139.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABT - Latest Insights

ABT
Nov 04, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $115.48
Real-time Price: $109.92 info
Change: -$5.56 (-5%) info
Market Cap: $190.221B info
ABT
Oct 21, 2026, 8:53 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $98.21
Real-time Price: $109.92 info
Change: +$11.71 (+12%) info
Market Cap: $190.221B info
ABT
Oct 21, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $99.52
Real-time Price: $109.92 info
Change: +$10.40 (+10%) info
Market Cap: $190.221B info
ABT
Oct 21, 2026, 7:32 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $100.55
Real-time Price: $109.92 info
Change: +$9.37 (+9%) info
Market Cap: $190.221B info
ABT
Oct 21, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.52
Real-time Price: $109.92 info
Change: +$9.40 (+9%) info
Market Cap: $190.221B info